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Abstract Mass transfer of deposited drug particles in the human lungs is an important factor
in the effective drug delivery by inhalation. This study is focused on the basic research related
to the possible acceleration of drug penetration toward the intended site of action through the
barrier created by mucus layer. It is proposed that beneficial effect can be obtained by altering
the mucus structure by inhaled functional carrier particles (FCPs) which are used to enhance
pulmonary delivery of aerosolized powder drugs and simultaneously contain mucolytics (e.g.,
N-acetylcysteine: NAC). The FCPs were prepared by an optimized spray-drying technique
and tested regarding their influence on the rheology of the reconstructed bronchial mucus and
the transport rate of model drugs (Rhodamine B and Disodium Cromoglycate). The results
indicate that the viscosity of mucus with high mucin concentration (i.e., reflecting a disease
is reduced by up to 42 % depending on the concentration of added FCPs what is similar
to the effect of pure NAC. Simultaneously, the effective diffusion coefficient Deff of the
model drug through the mucus increased from 23 × 10−7 (pure mucus) to 42 × 10−7cm2/s
(mucus modified by FCPs), and it was comparable to the effect obtained with pure NAC
(51 × 10−7cm2/s). The results confirm that using mucolytics incorporated into powder
particles (drug carriers) may be used to enhance mass transfer of inhaled aerosol drugs
across the bronchial mucus layer.
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1 Introduction
Inhalation of aerosolized drugs is the most efficient method of therapy of the respiratory tract
diseases, regardless of two natural mechanisms that play key role in protection of the human
respiratory tract against negative influence of pathogens and pollutants present in inhaled air
(Gradon´ and Marijnissen 2003). One of these mechanisms is related to airway tree structure
which causes that majority of inhaled particles (including drugs) cannot penetrate to the
lower parts of the lungs. Only particles with clearly defined aerodynamic diameter (below
5 µm) can overcome this barrier and deposit in the tracheobronchial tree with relatively high
efficiency. However, such as any other deposited strange matter, they are removed from the
surface of the respiratory tract by second defense mechanism, called mucociliary clearance,
which transports particles to the upper airways. The effective aerosol therapy requires that
bath barriers are overcome.
In this paper, we focus on the role of the functional carrier particles (FCPs) which have
been proposed as novel excipients in dry powder inhalers (DPIs) which may help to achieve
this goal and ensure more efficient inhalation therapy (Odziomek et al. 2012). Briefly summa-
rizing this concept, it is based on the fact that viscous properties of tracheobronchial mucus
significantly affect the rate of absorption and action of drugs administered by the pulmonary
route (Varum et al. 2010), so the natural way to improve this situation is simultaneous deliv-
ery of drug and mucoactive agent in the form of inhalation of rationally designed powder.
Changes in mucus composition which are typically associated to diseased conditions, result
in modification of mucus crosslink density and—as a consequence—in its rheological prop-
erties. In asthma, COPD or cystic fibrosis mucus viscoelasticity is increased by several times
what significantly disturbs the function of “mucociliary escalator.” Thickness of mucus layer
becomes much higher than normally (up to 100–200 µm), so the effectiveness of transmu-
cosal penetration of inhaled drugs is significantly reduced (Cone 2009; McGill and Smyth
2010).
The main components of mucus with the biggest influence on its rheological properties
(except water) and crosslink density are glycoproteins known as mucins. Mucins are built
up of subunits that are bound to each other by covalent bonds (disulfide bridges) between
cysteine residues. In addition to mucins, a large number of other constituents are present in
the mucus at lower concentrations, such as proteins, lipids, cellular and serum macromole-
cules, DNA, and electrolytes (Sanders et al. 2000). The gel-like behavior of mucus arises
mainly from physical chain entanglements and intermolecular interactions between mucins.
However, mucins can also interact with DNA, proteins, and lipids (Bansil and Turner 2006).
All these interactions (covalent bonds, ionic bonds, hydrogen bonds, and van der Waals
forces) enhance the viscoelasticity of mucus and establish a network structure (King 2005).
As empirical results indicate the average pore size of the tracheobronchial mucus in cystic
fibrosis is in the range of 100–200 nm (Matsui et al. 2006). It is clear that transport of particles
or molecules with higher diameter than mucus mesh pore size will be retarded. However,
also transport of smaller molecules is inhibited in polymer solutions like mucus. Partly, it
can be explained by electrostatic or hydrophobic interactions between diffusing molecules
and mucus compounds (Bhat et al. 1995; Meaney and O‘Driscoll 1999; Mortazawi 1995).
However, it is not sufficiently comprehensive explanation of these phenomena. The poly-
mer may also influence solute diffusion in other way. The presence of impenetrable, slow
moving polymer molecules in a solution may lead to an increase in the path length for dif-
fusion. Solute movement may be also retarded by increased hydrodynamic drag. In general,
the diffusivity of a solute through physically cross-linked polymer solution decreases as
cross-linking density increases. This phenomenon was discussed in many papers and can be
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Fig. 1 Concept of FCP activity
described, by many models, e.g., free volume theory (Flynn et al. 1974; Muhr and Blanshard
1982; Wesselingh 1993). As observed, reduction of length of polymer chains takes effect in
a faster transport of solutes through the mucus (Gao and Fagerness 1995). It was confirmed
by clinical trials. In some cases, improvement in the efficacy of treatment of respiratory tract
diseases (e.g., asthma, COPD, and cystic fibrosis) may be achieved by direct administra-
tion of the mucolytic agents, such as N-acetylcysteine (NAC), dithiothreitol, bromhexine, or
erdosteine, prior to inhalation of the dedicated drug. Mucolytics delivered typically as liquid
aerosol (droplets made of mucolytic solution) modify the mucus structure by splitting glyco-
proteins into smaller subunits by reduction of disulfur bonds. Consequently, the mucus loses
its viscoelastic properties and becomes more ‘transparent’ for drug molecules penetration
(Ferrari et al. 2001; Stern et al. 1998).
The proposed concept of FCPs allows avoiding the need of the sequential treatment,
since mucolytics are incorporated directly into solid particles required as drug carrier in
powder formulations. According to this idea, the aggregates which are formed of FCPs
and drugs (as submicron or nanostructured particles), will deposit together (i.e. at the same
site) on the surface of the mucus layer in the respiratory tract, Fig. 1. In most cases, the
dissolution of amorphous powders does not limit the drug transport through mucus (Patton
et al. 2010). After fast powder dissolution, slow diffusion of a drug through the mucus layer
starts. Simultaneously, the mucolytic agent released from FCPs begins to modify the mucus
structure and facilitates the transport of the co-released drug molecules to the epithelial cells‘
receptors. In this way, the local mucolytic activity induced by one component improves
the penetration of the other component (drug) to the epithelial cells what may be favorable
especially in delivering of quick-relief and short-acting drugs. However, FCPs may also
facilitate transport of nanostructural particles to the inner mucus layer (sol layer) which is
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removed from tracheobronchial tree slower than the outer one (gel layer). Nanostructural
particles trapped in this layer can release drugs molecules for prolonged time, what may
minimize frequency of the required inhalations during a day (Almeida and Souto 2007;
Fischer et al. 2009; Lai et al. 2007; Wang et al. 2008; Yoncheva et al. 2005).
In the previous work (Odziomek et al. 2012), we have shown that FCPs can be conveniently
produced by spray drying in controlled conditions using appropriately selected aqueous
precursors containing compounds currently approved for pharmaceutical use, such as N-
acetylcystine, or which are waiting for the approval—like low molecular-weight dextran
(LMWD). Dextran was used as the stabilizer of prepared powder particles because pure NAC
forms hygroscopic crystals which are unsuitable for inhalation. Incorporation of the LMWD
allows delivering mucoactive particles to the tracheobronchial tree in the form of aerosol
released from a dry powder inhaler (DPI). In addition, LMWD is a convenient adjuvant in
this case since it shows mucolytic properties itself and may also improve the mucociliary
clearance. According to literature data, dextran acts probably by an osmotic mechanism
(attraction of fluid into the airway milieu) and additionally by disruption of the network
crosslinks between neighboring mucin macromolecules (Feng et al. 1997; Hirji et al. 1998;
King and Rubin 2002; Sudo et al. 2000).
We used mixtures of LMWD and NAC in proportion—4:1 and 1:1. The optimum condi-
tions of the spray drying process for obtaining FCPs (drying air temperature: 120 ◦C, solution
feed: 3 ml/min, aspirator rate: 37 m3/h, airflow: 0.475 m3/h, and outflow temperature: 55 ◦C)
allowed to maximize powder yield and the content of particles smaller than 5 µm (fine par-
ticle fraction—FPF), i.e., particles expected to penetrate and deposit in the tracheobronchial
tree with the highest efficiency (Heyder 2004; Koushik and Kompella 2004). Both, FPF
and mass median aerodynamic diameter (MMAD) obtained after dispersion of FCPs from
a commercial capsule-type DPI (FPF: 46–51 %, MMAD: 2.28–2.43 µm) indicate that these
aerosols should have high deposition in the respiratory tract and, in consequence, they are
applicable in pulmonary drug delivery. Moreover, the relatively high glass transition tem-
perature Tg (51–61 ◦C) of the composite material of FCPs should minimize the tendency
to recrystallization which is typical for amorphous solids. In consequence, it should ensure
stability of their most important parameters during storage (Odziomek et al. 2012).
However, as it was noted earlier, effective deposition in the target area in the lungs is
only the first step of drug delivery—the second one is its transport through the mucus.
Although it is well known that NAC delivered to the lungs as aerozolized aqueous solution
decreases mucus viscosity in the airways, there is still no information about the influence
of NAC delivered as powder on mucus rheology (viscosity) and on the mass transfer in the
mucus layer. Therefore, this study is focused on determination how each chemical com-
pound present in the FCP influences mucus properties and, finally, if a synergic effect of all
components may be obtained using FCPs. We limit this research only to FCPs character-
ized with the best aerodynamic performance and stability (Odziomek et al. 2012) and two
types of mucin solutions used to reflect properties of natural mucus in different physiological
states.
2 Materials and Methods
2.1 Materials
N-acetylcysteine (NAC, A7250), low molecular-weight dextran (LMWD, 31388), and mucin
(type II, M2378) were purchased from Sigma–Aldrich (USA). Rhodamine B, phosphate
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Table 1 Content of functional carrier particles and their components in mucus samples with both considered
mucin concentrations
Components added to mucus Content in the mucus (% w/w)
NAC 0 (0.25) 0.5 (0.75) 1 1.5 2.0
LMWD (Dextran 4000 Da)
Functional Carrier NAC/Dextran 1:1 (FCP1)
Functional Carrier NAC/Dextran 1:4 (FCP2)
Values in brackets concern samples with higher mucin concentration only (20 % w/w)
buffer, and sodium azide were purchased from POCH (Poland). Disodium Cromoglycate
(DSCG) was donated by GSK Pharmaceuticals SA (Poland). Water used for preparing mucus
solutions and for other analytical purposes were purified by reverse osmosis—RO (Puricom,
USA).
2.2 Preparation of Reconstructed Bronchial Mucus
The artificial bronchial mucus model was reconstructed from the main component of natural
mucus–mucin, according to the information from different literature sources (Bhat et al.
1996a, b; Dawson et al. 2004; McGill and Smyth 2010). According to manufacturer’s data,
the selected mucin was not modified by proteolic enzymes, so its natural structure should
be preserved. Its final concentration after dissolution in the phosphate buffer (7.4 pH) was
adjusted to 10 and 20 % w/w. The pH value was precisely controlled and, if necessary,
adjusted with NaOH aq. solution. A small amount (0.02 % w/w) of sodium azide was added
to protect the samples from microbial contamination. After setting the pH value and adding all
components, mucus samples were gently stirred for 6 hours at a 37 ◦C. Preparation of different
samples required addition of the strictly defined amounts of investigated compounds (data
shown in Table 1). After the addition, pH was adjusted again, if necessary. Modified mucus
samples were stirred with the same intensity during additional 2 hours at constant temperature
(37 ◦C).
2.3 Determination of the Apparent Mucus Viscosity
Rheological data for prepared mucus samples were obtained with a rotational rheometer
(Smart—Fungilab, Spain) equipped with two different spindles: LCP and TL5, designed
for measurements in samples of significantly different viscosities (like samples with 10 and
20 % w/w mucin concentration). For a straightforward comparison of the results, all mea-
surements were done at the same rotational speed of a spindle (6 rpm) and at similar shear
rate γ˙ ≈ 8 s−1 which lies within the range found in bronchial mucus at normal physiolog-
ical conditions (0.1–20 s−1) (Cone 2009). Since the mucus is a non- Newtonian fluid, we
characterize its rheology by “apparent viscosity” understood as the viscosity measured at
the physiological strain rate, which was applied in our studies. All viscosity measurements
were taken at constant temperature 37 ◦C (physiological conditions). In the first two series,
the influence of each component of functional carrier particles (LMWD, NAC) was analyzed
separately. In each series, the samples were studied during a successive increase of the con-
centration of added components (0.25–2 % w/w). In the last two series of measurements, the
influence of functional carrier particles (FCP1, FCP2) on mucus viscosity was investigated.
The composition of tested mucus samples is shown in Table 1.
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Fig. 2 Scheme of a typical diffusion chamber used to measure drug transport through the artificial mucus
2.4 Mass Transfer Rate Through the Mucus Layer
Mass transfer studies were done for Rhodamine B and disodium cromoglycate (DSCG) as
model drugs. Their effective diffusion coefficient Deff in the mucus was measured using
diffusion chamber method (Fig. 2).
The chamber has three compartments: a donor and a receiver (volume of each: 5 ml)
separated by a thin layer of mucus solution restricted by two PVDF (polyvinyl difluoride)
Durapore membranes (pore size 0.1 µm, thickness 0.125 mm—Millipore, USA). The central
holder had thickness of 3 mm and contained a fixed volume of mucus (300 µl), which was
injected with a syringe through a port on the top of this unit. The membranes were selected
according to literature data (Norris and Sinko 1997) to avoid any leakage.
The donor compartment was filled with a solution containing either Rhodamine B (con-
centration of 0.05 mg/ml) or DSCG (concentration of 0.1 mg/ml. The receiver part was filled
with the pure phosphate buffer (pH 7.4). Solutions in both compartments were gently agi-
tated by magnetic microstirrer (300 rpm) to reduce the local mass transfer resistance near the
membrane surface by hydrodynamic mechanism. The mucus layer was stagnant. A sample
from receiver compartment sample was taken after approximately 5 min to check for any
leaks. During whole experiment (6 hours), samples for analysis were taken from the receiver
at 30 min intervals. The content of Rhodamine B in was determined using fluorescence spec-
trometer (Lumina—Thermo Scientific, USA) at the excitation and emission wavelengths
of 555 and 580 nm, respectively. In case of DSCG, the concentration in samples was mea-
sured with HPLC system (model Infinity 1220, Agilent Technologies, USA) equipped with
UV–Vis detector and 100 mm length ZORBAX Eclipse Plus C18. DSCG was analyzed at
325 nm wavelength. Compositions of mucus studied in this part of investigations are shown
in Table 2.
The experiments were run in triplicate and their results were expressed as the mean ±
standard deviation.
The effective diffusion coefficient in the mucus layer, Deff , was calculated from the appro-
priate solution of the Fick’s law with the assumption of the steady-state process (Desai and
Vadgama 1991). It was also assumed that membrane resistance is negligible and the mass
transfer resistance at the membrane surface in both diffusion chambers is eliminated by stir-
ring. Accordingly, the main resistance of mass transfer from donor phase to acceptor phase
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Table 2 Content of functional carrier particles and their components in mucus samples with mucin concen-
tration (20 % w/w)
Components added to mucus Content of examined substances in the mucus (% w/w)
NAC 0 0.5 1.0 (2.0)
Dextran (4000Da)
functional carrier NAC/Dextran 1:1 (FCP1)
Value in bracket concern samples with 10 % w/w mucin concentration
Fig. 3 Indications and
concentration profile in diffusion
chambers
is located in the mucus layer of known thickness. For the assumed steady-state diffusion, the
time necessary for solute transport through mucus, tD mucus, is significantly shorter than the
time necessary to change its concentration in the diffusion cells, tc. This is correct only if the
volume of mucus is significantly smaller than cells volume (Truskey et al. 2009), which is
true for our system.
In this situation, mass flux of a solute transported from donor chamber to acceptor part
can be expressed as




because the concentration distribution in the mucus layer is described by linear function
(Fig. 3)
C(x) = C1 + (C2 − C1) xL (2)
where C1—concentration of analyzed substance in donor compartment (and for x = 0), C2—
concentration in the acceptor compartment (and for x = L), x—is the horizontal distance
measured from the surface of the membrane in the donor compartment, and L—thickness of
the mucus layer.
As the measurements were conducted in closed system, the concentration of analyzed
substances in both diffusion chambers should change during the experiment and, for suffi-
ciently long time, the concentration in both compartments will equalize. However, because
of limited time of measurement (6 hours), the solute concentration in the donor chamber was
always at least two orders of magnitude higher than in the acceptor chamber. In each trial,
the linear relationship of concentration against time was obtained (R2 = 0.95–0.99) what
confirms that process was realized under the quasi-state conditions. Therefore, we can write

































Concentration in the mucus [% w/w]
NAC LMWD FCP1 (NAC/Dextran - 1:1) FCP2 (NAC/Dextran - 1:4)
Fig. 4 Comparison of the apparent viscosity of the artificial bronchial mucus modified by functional carrier
particles (FCPs) and their components. Average ± SD, number of replicates = 3
where A—the surface area of mucus available for mass transfer, dmdt —the slope of the straight
line in the graph of m (total amount of solute transferred through the layer) versus t (time)
at steady state,
Described procedure of determination of the effective diffusion coefficient is similar to
the presented by other authors (Brodin et al. 2010; Desai and Vadgama 1991; Shaw et al.
2004).
3 Results and Discussion
As the first step, it was checked if FCPs have ability to modify the structure of artificial
mucus. This was determined by viscosity measurements of mucus samples (10 and 20 %
w/w of mucins) after addition of strictly defined amounts of FCPs and their components
(Table 1). The pH value of mucus samples was carefully controlled at physiological value
(7.4) to ensure measurement accuracy and repeatability. Changes in pH could induce mucins
gelation, which involves interactions of side chains of amino acids with pKs around 4, such
as Asp or Glu from the non-glycosylated regions of the molecule. At neutral pH (6–7),
these non-glycosylated Cys-rich regions of mucins are conformed with hydrophobic domains
hidden in the folds stabilized by the salt bridges between negatively charged carboxylates
and positively charged amino groups. At acidic conditions (pH 2), the carboxylates of the
salt bridges are protonated what results in breakage of the bridges, unfolding and exposure of
hydrophobic regions of protein. In effect, the number of disulphide bonds between cysteine
residues is much greater in acidic environment than at neutral pH, and this increases the
cross-linking density in the mucus, so its viscosity. High importance of pH control is also
related to the activity of mucolytics such as NAC. The mechanism of its action is related to
the thiol-disulfide exchange and it is inhibited at low pH, when the protonated thiol form is
more favored than deprotonated thiolate form (Bansil and Turner 2006).
The results are presented in Figs. 4, 5. Viscosity of unmodified mucus samples with higher
mucins concentration (20 % w/w) measured at physiological value of shear rate (∼ 8 s−1)
was 289.4 ± 7 mPa s. It corresponds well to the viscosity of the natural mucus in diseased
conditions like asthma (146–310 mPa s) or cystic fibrosis (app. 160 mPa s) when mucins
concentration in bronchial mucus is significantly increased (Rubin 2007). Similarly, the
viscosity of samples containing 10 % w/w mucins which equals 16.2 ± 0.1 mPa s, is in a
good agreement with viscosity of bronchial mucus of healthy subjects (Serisier et al. 2009).
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Concentration in the mucus [% w/w]
NAC LMWD FCP1 (NAC/Dextran - 1:1) FCP2 (NAC/Dextran - 1:4)
Fig. 5 Comparison of the apparent viscosity of the artificial bronchial mucus modified by functional carrier
particles (FCPs) and their components. Average ± SD, number of replicates = 3
Based on the data presented in Figs. 4, 5, it can be found that the viscosity of mucus which
contains higher contents of mucins is meaningfully reduced in a concentration-dependent
manner after addition of pure NAC and FCPs containing NAC. It probably results from
gradual breakage of sulphur bonds between mucin molecules. These results also demonstrate
that activity of NAC included in the FCPs is preserved after the spray drying process. Higher
NAC content always decrease mucus viscosity. It is clearly visible both for samples that
contain pure NAC and samples with functional carrier particles containing NAC and dextran
in different proportions. The viscosity reduction caused by particles denoted as FCP1 is
at average 10–15 % stronger than induced by FCP2. It can be a consequence of a higher
content of dextran (LMWD) as the second component of FCPs. The results obtained for pure
LMWD added to mucus show that this polysaccharide slightly (by 10–20 %) increases mucus
viscosity (Fig. 4). This observation may confirm that mucolytic activity of dextran observed
in vivo is mainly related to the osmotic mechanism, which is absent in the studied artificial
system.
The highest reduction of viscosity (by 53 % in relation to the blank sample) was obtained
for pure NAC at 1.5 % (w/w) content in the mucus. For 1 % (w/w) content of FCP1, the original
viscosity of the mucus was reduced by 50 %. These values should ensure an improvement of
the mucociliary clearance rate in the respiratory tract in disease conditions.
For convenient comparison of the obtained results with literature data, the logarithm of the
quotient of viscosities: of mucus samples and water, is calculated and listed in Table 3. In all
our measurements, the calculated logarithm value is in the range of 2.29–2.40, which closely
corresponds to the results reported by Cone et al. and Lai et al., i.e. 2.5±0.5 (Cone 2009; Lai
et al. 2009). After mucus modification by pure NAC or by both types of functional carrier
particles (FCP1, FCP2), the calculated logarithm values decrease to 2.08–2.13 indicating the
evident thinning effect.
In the case of mucus model with the lower mucin concentration (10 % w/w), the effect of
FCPs is not as clear as at the higher concentration (Fig. 5). Particles with equal proportion
of LMWD and NAC (FCP1) slightly reduce viscosity, while particles with four times higher
content of LMWD in relation to NAC (FCP2) cause increase of mucus viscosity similarly to
pure LMWD. These results suggest that mucolytics incorporated into FCPs do not change
mucus structure significantly.
The second part of measurements was aimed at determining the effective diffusion coef-
ficient Deff of Rhodamine B and DSCG in artificial mucus. In vitro methodologies which
can be applied for characterization of the molecules mobility in biogels, like mucus, can
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Table 3 Effect of the functional carrier particles, dextran and pure NAC on the logarithm of the quotient
of viscosities: of mucus samples with 20 % w/w mucin concentration and water (SD— standard deviation,
number of repeats: n = 3)
Components Content of examined substances in the mucus (% w/w)
0 0.25 0.5 0.75 1 1.5 2.0
NAC Log(µmucus/µH2O) 2.40 2.20 2.17 2.14 2.11 2.08 2.10
SD (−) 0.03 0.17 0.19 0.13 0.02 0.01 0.15
Dextran (4000Da) Log(µmucus/µH2O) 2.36 2.33 2.33 2.34 2.34 2.35 2.37
SD (−) 0.04 0.08 0.04 0.05 0.06 0.05 0.15
FCP1 NAC/Dextran 1:1 Log(µmucus/µH2O) 2.37 2.25 2.18 2.08 2.07 2.08 2.10
SD (−) 0.03 0.21 0.09 0.08 0.17 0.37 0.28
FCP2 NAC/Dextran 1:4 Log(µmucus/µH2O) 2.36 2.29 2.17 2.15 2.11 2.13 2.16
SD (−) 0.05 0.17 0.12 0.14 0.18 0.10 0.08
be divided into two categories: those measuring the overall drug transport, and the methods
that measure the mobility of the drug in local microregions of the biogel. The first group
includes the diffusion chamber and semi-infinite slab method (Larhed et al. 1997; Westrin et
al. 1994), while the second— fluorescence recovery after photobleaching (FRAP) (Meyvis et
al. 1999; Saltzman et al. 1994). Each method has some strong and weak features, however, if
information on the drug transfer through the biogel layer to the target (e.g., epithelial cells of
the lower airways) is needed, the recommended technique should allow for the measurement
of the overall drug transport rate (Sanders et al. 2000). It justifies the methodology applied
in this work, i.e., the diffusion chamber approach. One of the most important features of this
method is possibility of simulating various disease states or physiological conditions by alter-
ing the mucus composition due to addition of selected substances. Simultaneously it should
be noted that in in vivo conditions mucus layer is continuously agitated by epithelial cells‘
cilia. Therefore, the estimation of diffusion coefficient in diffusion cells where the mucus
layer is stagnant is only approximation of drug transport in natural conditions. Regardless of
this fact, this is still commonly used technique for this kind of measurements.
As the model substances for mass transfer studies were chosen Rhodamine B and antiasth-
matic drug—Disodium Cromoglycate (DSCG). The first reason is their molecular mass (479
and 468.3 Da respectively) which is similar to the molecular mass of many drugs used in the
treatment of respiratory tract diseases (e.g., budesonide—430.5 Da, fluticasone propionate—
500.5 Da, formoterol fumarate - 344.4 Da). Secondly, they have properties which significantly
simplified the selective and sensitive quantitative determination of transferred material by
spectrofluorimetry (Rhodamine B) and spectrophotometry (DSCG).
The composition of analyzed samples and results obtained for rhodamine in mucus reflect-
ing disease conditions are shown in Table 4.
Calculated values of the effective diffusion coefficient Deff indicate the relationship
between the composition and structure of mucus samples, and the mass transfer rate through
the mucus layer. The effective diffusion coefficient of Rhodamine B (molecular mass,
Mr = 479) calculated for unmodified mucus reflecting disease conditions (mucin con-
centration: 20 % w/w) is 23.1 × 10−7 cm2/s what is approximately 5 times lower than
its diffusion coefficient Deff found in a pure buffer solvent (118.9 × 10−7 cm2/s). This
value is in agreement with the literature data for substances with similar molecular mass:
phenolphthalein (Mr = 318, D = 18 × 10−7 cm2/s) or phenolphthalein diphosphate
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Table 4 The effective diffusion coefficients Deff for Rhodamine B in mucus samples reflecting disease (20 %
w/w mucin concentration), following the addition of mucoactive compounds (SD – standard deviation, number
of repeats – n = 3)
Components added to mucus Content of examined substances in the mucus (% w/w)




23.06 31.36 47.99 50.97
SD 3.67 3.65 5.24 5.23
Dextran (4000 Da) Effective diffusion
coefficient Deff ·
10−7(cm2/s)
23.06 25.46 32.19 25.0
SD 3.67 2.10 4.7 6.1
FCP1 NAC/Dextran 1:1 Effective diffusion
coefficient Deff ·
10−7(cm2/s)
23.06 29.50 42.31 37.02
SD 3.67 4.93 3.21 6.22
(Mr = 566, D = 33 × 10−7 cm2/s), transported through the native porcine mucus (Desai
and Vadgama 1991).
Measurements for mucus modified by pure dextran show a slight increase in value of Deff
(up to 32 × 10−7 cm2/s) for dextran concentration in the mucus below 1 % w/w. Above this
concentration, Deff coefficient decreases which is probably related to the increasing crosslink
density in the mucus (by analogy, this effect induces higher viscosity of the mucus). Deff
coefficient for Rhodamine B calculated in mucus with an increasing content of NAC as the
main mucolytic ingredient of functional carrier particles, is higher than in the blank sample
and equals almost 51×10−7 cm2/s (at 2 % w/w NAC content). Deff in the mucus modified by
particles FCP1 at 1 % w/w concentration, reaches a maximum value of 42.31 × 10−7 cm2/s.
Higher contents of FCP1 in the mucus cause a decrease of Deff which may be attributed to
the presence of dextran incorporated into the FCP (i.e., to increase of viscosity).
The obtained results clearly indicate that the destruction of the mucus structure, which
is also related to changes in viscosity, has an influence on the diffusive transport rate of
low molecular-weight molecules (Rhodamine B, Mr = 479). However, considering that the
average pore size in natural mucus is in the range of 100 to 400 nm (Cone 2009), it can be
expected, that even in case of macromolecular drugs like peptides or proteins with an effective
molecular size of 2–15 nm, diffusion should be not drastically retarded (Sanders et al. 2000).
Some studies confirm this hypothesis. e.g., work of Saltzman et al. (1994) showed that large
macromolecules of human antibodies (IgA: Mr = 150 kDa, IgM: Mr = 970 kDa) readily
diffused without restrictions in human cervical mucus (Dmucus/Dwater = 0.99 and 0.89 for IgA
and IgM, respectively). Szentkuti (1997) obtained similar results for dextran macromolecules
with different molecular masses (10–70 kDa) diffusing in the mucus of distal colon of rats.
On the other hand, Desai and Vadgama (1991) showed that the diffusion of macromolecules
like: lysozyme (14.4 kDa), rennet (35 kDa), BSA (68 kDa), and glucose oxidase (186 kDa)
through the native gastric porcine mucus was reduced 10- to 30-fold in comparison to the
diffusion in aqueous solution. Similar observations to ours were also done in the work of
Larhed et al. (1997), where two drugs of almost equal molecular weight (approximately
two times larger than Rhodamine B), the lipophilic peptide cyclosporin (1204 Da) and the
hydrophilic peptide D-arginine vasopressin (1194 Da), diffused with the same rate in pig
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Table 5 The effective diffusion coefficients Deff for DSCG in mucus samples with 10 % w/w mucin con-
centration, following the addition of mucoactive compounds (SD – standard deviation, number of repeats –
n=3)
Sample composition Deff · 10−7cm2/s (±SD)
Mucin (10 % w/w) 95.2 ± 2.6
Mucin (1 % w/w) + NAC (2 % w/w) 100.7 ± 2.2
Mucin (1 % w/w) + LMWD (2 % w/w) 91.7 ± 1.5
Mucin (1 % w/w) + FCP1 (2 % w/w) 98.7 ± 1.3
intestinal mucus, with the rate approximately 6 times slower than in the phosphate buffer.
The explanation of these phenomena was mentioned earlier. As a reminder, the presence of
impenetrable, slow moving polymer molecules in a solution may lead to an increase in the path
length for diffusion. Solute movement may be also retarded by increasing the hydrodynamic
drag experienced by the solute as discussed in several papers (Flynn et al. 1974; Muhr and
Blanshard 1982; Wesselingh 1993).
Differences between the mentioned above results obtained by several authors can be partly
explained by the variety of measurement methods, mucus models and transported molecules
used in the separate studies. Probably the largest impact has the fact that the majority of the
mentioned studies used the native mucus which could lead to significant differences in the
composition of the analyzed mucus samples. It is recognized that the composition has an
influence on mucus crosslink density but also on the intensity of other interactions (e.g. ionic,
osmotic, hydrophobic) between mucus components and diffusing molecules.
Selection of Rhodamine B as a model drug allows for neglecting the majority of interac-
tions between mucus components and the transferred compound. Due to hydrophilic charac-
ter, this molecule should not exhibit hydrophobic interactions with mucins and other mucus
components (lipids, hydrophobic domains in proteins) (Zhang et al. 2011). Moreover, mucins,
are negatively charged due to the presence of N-acetylneuraminic acid and sulfated sugars
(Carlstedt et al. 1985). Charge of nucleic acids is also negative. Rhodamine B at physiological
conditions (pH 7.4) has a neutral charge (it is hold in pH range 6.0–10.8), therefore it cannot
be bounded with the basic mucus components through electrostatic interactions (Garcia et
al. 2005; Oh et al. 2008; Schrum et al. 2000).
A large increase of diffusion coefficient after mucus modification by the mucolytic agent
also confirms that neither electrostatic nor hydrophobic interactions limit the mass transfer
of the drug. It can be concluded that, therefore, the key factor is the crosslink density of the
mucus network. The measured influence of pure NAC or FCPs on the drug transport may be
slightly overrated, since we used the model with a higher mucin concentration (20 %) than
in natural mucus. Samples with lower mucin content (10 % w/w) modified by the addition of
NAC, LMWD, and FCP1 (2 % w/w) effective diffusion coefficient were only slightly changed
(Table 5).
Simultaneously, these Deff values were much higher than those obtained for more con-
centrated mucus, and this leads to correlation between the apparent viscosity of the mucus
and the effective diffusion coefficient (Fig. 6).
Finally, it should be noted that in the natural mucus, there are also other ingredients
present which are not the target for mucolytic agent. Additionally, the effect caused by
mucus modification using FCPs may be not so clear if molecules with different hydrophobic
properties and electrostatic charge are transported through the mucus layer. Therefore, further
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Mucin without modification (10%) Mucin (10%) + modification (2%) Mucin without modification (20%)
Mucin (20%) + NAC Mucin (20%) + LMWD Mucin (20%) + FCP1
Fig. 6 The value of effective diffusion coefficients as a function of apparent viscosity of analyzed samples
investigations will be needed to characterize more precisely the influence of FCPs on diffusive
transport of different drugs in the mucus layer.
4 Conclusions
Drug delivered by inhalation may not reach efficiently the target cells due to a low permeabil-
ity of the mucus which is very viscous during lung disease. According to proposed concept of
functional carrier particles (FCPs), we incorporated two mucolytic agents: N-acetylcysteine
(NAC) and low molecular-weight dextran (LMWD) into solid particles prepared by spray-
drying which may be used as drug carriers in aerosol delivery to the lungs using dry powder
inhalers (Odziomek et al. 2012). In the current studies, it was demonstrated by in vitro
methodology that FCPs indeed may be used to reduce mucus viscosity and increase mucus
permeability (i.e., diffusion rate for model drugs). To reflect the properties of natural mucus
in different physiological states, the measurements were done for solutions with different
concentrations of mucins. The results of this research indicate the relationship between the
composition and rheological properties of model mucus, and the mass transport rate. In the
case of mucus reflecting diseased conditions, N-acetylcysteine, both pure and incorporated
into FCP, decreases mucus viscosity, and increases the transport rate of studied drugs. For
another FCP component, dextran, which has to be incorporated into FCPs to increase powder
stability, only a slight increase of mucus viscosity is observed, and the mass transfer rate is
changed very little. At the same time, there was no evident effect in case of mucus with a
lower content of mucins (i.e. without disease).
Comparing mucoactivity of the FCPs to the effects measured for their pure individual
components, it was possible to demonstrate that FCPs preserve mucolytic activity of the
precursor compounds, and that these particles act as enhancers of mass transfer in case of
a viscous mucus (lung disease conditions). The obtained results indicate that the concept
of FCPs may be useful for pulmonary drug delivery. Obviously, more investigations are
needed for a more detailed description of the influence of FCPs on molecular transport
through the mucus. Wider representation of drugs with diverse molecular mass, charge, and
hydrophobicity should be examined for a better understanding of interactions between mucus,
FCPs and the diffusing molecules. The more complete picture of the process may be obtained
by incorporating the results of theoretical predictions from molecular dynamics simulations.
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Such studies are currently underway in a wider cooperation (Gniewek and Kolin´ski 2012;
Sosnowski et al. 2012).
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